Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering
Retrieved on:
Tuesday, October 11, 2022
Diamond, Inner nuclear layer, EN, AMF, CET, Retinal degeneration, Geographic atrophy, Neural engineering, PRIMA, Total, Vance DeGeneres, Moorfields Eye Hospital, Primavera, Retina, Research, Mnemos EP, Optical coherence tomography, Risk, Institute, Nervous system, University, Company, INL, Vision Institute, Rehabilitation, Safety, Journal, IMO, UPMC, Stanford University, AMD, Medical device, Patient
Previously, the data from the French feasibility study already demonstrated that the Prima System is well tolerated.
Key Points:
- Previously, the data from the French feasibility study already demonstrated that the Prima System is well tolerated.
- The data in this paper now further demonstrate the stability and minimal impact of the implant once in position.
- Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
- Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD).